Clinical trials: IgAN - IgA Nephropathy
IgA Patients, Hydroxychloroquine
A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy
The investigators study will recruit IgA nephropathy patients with proteinuria range from 0.75 to 3.5g/d even after three-month treatment by sufficient ACEi/ARB.
- Trial name
- NCT02942381
- Testing
- Hydroxychloroquine Sulfate
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University First Hospital
Lupus Nephritis, IgA Nephropathy
The Correlation of Periostin and Renal Pathology in Chronic Kidney Disease Patients
The purpose of this study is to determine the location of periostin and urine periostin level in patients with lupus nephritis and IgA nephropathy.
- Trial name
- NCT02493101
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Chulalongkorn University
IgA Nephropathy (IgAN), Immunoglobulin A Nephropathy (IgAN)
Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN)
This multicenter, single-arm, open-label Phase 4 pilot study evaluates the effects of atrasentan added to optimized supportive care on kidney structure and function in adults with biopsy-confirmed IgA nephropathy.
- Trial name
- A-MECH (NCT07820995)
- Testing
- atrasentan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Illinois Chicago
IgA Nephropathy
Efficacy and Safety of Atacicept in IgA Nephropathy
This main purpose of this study was to evaluate the safety, tolerability, dose response and efficacy of Atacicept in participants with IgA nephropathy and persistent proteinuria.
- Trial name
- NCT02808429
- Testing
- Atacicept 25 mg, Atacicept 75 mg
- Where
- 18 sites in United States, Japan and 1 more
- Volunteers
- 16 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association
Autoimmune Diseases, Systemic Lupus Erthematosus (SLE)
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B cell mediated autoimmune disease.
- Conditions
- Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy (IgAN)
- Trial name
- NCT07305116
- Testing
- UCAR T-cell
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
The primary objective of this study will be to evaluate the drug-drug interaction potential of CCX168 with concomitant medications, as either a perpetrator or a victim, following oral administration of CCX168 to healthy…
- Trial name
- NCT06004947
- Testing
- CCX168, Midazolam, Celecoxib
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Amgen
IgA Nephropathy (IgAN)
Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
Evaluate the efficacy and safety of HSK39297 tablets in patients with primary IgAN
- Trial name
- NCT07390123
- Testing
- HSK39297
- Where
- 9 sites in China
- Volunteers
- 370 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Glomerulonephritis, IGA
ACEi/ARB Alone Versus ACEi/ARB Plus Steroids in the Treatment of Primary IgA Nephropathy, a RCT
IgA nephropathy( IgAN) is the most common primary glomerulonephritis worldwide. Since the etiology of the disease is not clearly understood, no specific therapeutic strategies was defined for IgAN.
- Trial name
- NCT00378443
- Testing
- prednisone + Inhibace/Cozaar, Inhibace/Cozaar
- Sponsor
- Peking University
Primary IgA Nephropathy
A Study of SHR-2173 in Participants With Primary IgA Nephropathy
This study is a randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate the efficacy and safety of SHR-2173 in patients with Primary IgA Nephropathy(IgAN).
- Trial name
- NCT07354932
- Testing
- SHR-2173 injection
- Where
- 2 sites in China
- Volunteers
- 84 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
IgA Nephropathy (IgAN)
SLN12140 in Adult Participants With IgA Nephropathy in China
This study is a randomized, parallel, double-blind, placebo-controlled, subcutaneous administration Phase II dose-exploration clinical trial aimed at evaluating the efficacy, safety, PK, PD, and immunogenicity characteristics of…
- Trial name
- NCT07553494
- Testing
- SLN12140
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Linno Pharmaceuticals, Inc.
IgA Nephropathy, Kidney Transplant Recipients
MYTP01 for Immune-Mediated Diseases
The goal of this study is to evaluate whether MYTP01, a traditional Chinese herbal formula developed by clinical experts with the assistance of artificial intelligence (AI), is effective and safe as an additional treatment for…
- Conditions
- IgA Nephropathy, Kidney Transplant Recipients, Lupus Nephritis, Primary Membranous Nephropathy
- Trial name
- NCT07901764
- Testing
- MYTP01
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Zhejiang Provincial People's Hospital
IgA Nephropathy (IgAN)
RESistance of IgA Nephropathy to Conventional and Newly-approved Therapies: an Observational, Real-life Study (RESIGAN)
IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide, characterized by glomerular mesangial IgA deposits, often with IgG and C3. Despite its prevalence, the pathophysiology of IgAN is poorly understood.
- Trial name
- RESIGAN (NCT06926244)
- Where
- France
- Volunteers
- 800 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Primary IgA Nephropathy
Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis in the world.There is to date no curative therapy for patients with IgAN.It is considered that dendritic cells, Toll-like receptor (TLR) 9 and…
- Trial name
- HCQIgAN (NCT02765594)
- Testing
- Hydroxychloroquine Sulfate, Valsartan
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Peking Union Medical College Hospital
Primary Immunoglobulin A Nephropathy (IgAN)
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
The study is an open-label, single arm, multicenter, Phase III study to determine proteinuria reduction, pharmacokinetics (PK), safety and tolerability (including CV surveillance) of iptacopan in primary immunoglobulin A…
- Trial name
- NCT06994845
- Testing
- iptacopan
- Where
- 20 sites in United States, Argentina and 6 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
IgA Nephropathy
Fecal Microbiota Transplantation for Refractory IgA Nephropathy
IgA nephropathy (IgAN) is one of the most common glomerular diseases worldwide. Current treatments for IgAN are limited by their relatively insufficient efficacy and severe adverse events.
- Trial name
- NCT03633864
- Testing
- Fecal microbiota transplantation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Air Force Military Medical University, China
Immunoglobulin A Nephropathy
A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy
The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of povetacicept in participants with immunoglobulin A nephropathy (IgAN).
- Trial name
- NCT07807995
- Testing
- Povetacicept
- Where
- 4 sites in United States
- Volunteers
- 605 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Immunoglobulin A Nephropathy (IgAN)
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
In this study, researchers will learn more about the use of felzartamab in participants with immunoglobulin A nephropathy (IgAN). IgAN is a kidney disease caused by the buildup of an antibody called IgA in the kidneys over time.
- Trial name
- PREVAIL (NCT06935357)
- Testing
- Felzartamab
- Where
- 265 sites in United States, Argentina and 26 more
- Volunteers
- 454 people
- Sponsor
- Biogen
IGA Nephropathy
Calcitriol in the Treatment of Immunoglobulin A (IgA) Nephropathy
Immunoglobulin A (IgA) nephropathy is the most common type of primary glomerulonephritis in the world. A wealth of literature suggests that vitamin D and its analogs have profound effects on immune system function and glomerular…
- Trial name
- NCT00319761
- Testing
- Calcitriol
- Where
- Hong Kong
- Volunteers
- 10 people
- Sponsor
- Chinese University of Hong Kong
IgA Nephropathy
Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy
This is an open-label Phase 2a clinical study designed to evaluate the safety and efficacy of AVB-S6-500 in patients with IgA Nephropathy (IgAN). Approximately 24 patients will be enrolled.
- Trial name
- NCT04042623
- Testing
- AVB-S6-500
- Where
- 2 sites in United States, Ukraine
- Volunteers
- 1 people
- Sponsor
- Aravive, Inc.